Gastric cancer
Conditions
Interventions
A:DC-CIK with PD-L1 silenced
B:Ordinary DC-CIK
C:General treatment
Sponsors
Lanzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Clinical and pathological diagnosis of primary or recurrent gastric cancer with stage I-III, according to NCCN guidelines, 2017.V5, patients with radical or palliative surgery; 2. Aged 18-80 years male and female; 3. The estimated survival time is more than 12 weeks; 4. ECOG physical state score 0-2 or KPS functional state score = 70; 5. The results of the laboratory tests conducted during the first week of the group met the following conditions: Neutrophils (ANC)=1.5×10^9/L; Platelets (PLT) = 80 × 10^9/L, hemoglobin (Hb) = 100 g/L; Total bilirubin (TBI) = 2.5*upper limit of normal (2 mg/dl); Alanine aminotransferase (ALT), aspartate aminotransferase (AST) = 2*upper limit of normal; Blood creatinine (Cr), urea nitrogen (BUN) = 1.5*upper limit of normal; Coagulation parameters (INR and PTI in the normal range); 6. Patients participate voluntarily and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. T-cell lymphoma; 2. Those with severe allergic constitution, especially those with cytokine IL-2 allergy; 3. HIV-infected persons; 4. Acute infection, severe infection with uncontrolled or high fever; 5. Patients with severe immunodeficiency or autoimmune diseases; 6. Persons who have undergone bone marrow, stem cell or organ transplantation; 7. Patients who are using immunosuppressive drugs or who have been using immunosuppressants for a long period of time after organ transplantation; 8. patients with organ dysfunction and recent history of myocardial infarction (within 3 months); 9. Severe abnormal coagulation; 10. Pregnant or lactating women; 11. Persons with mental illness and severe depression, as well as persons with mental or addictive diseases that may affect their ability to give informed consent; 12. Patients without access to immunity and clinical follow-up evaluation, as well as patients with poor compliance; 13. Other researchers did not consider it appropriate to join the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dendritic cell surface markers;CIK surface markers;DC-CIK function detection;KPS score;Tumor lesions assessment;Peripheral blood lymphocyte subsets;Plasma cytokines;Tumor markers;Lymphocyte function test;Survival rate and survival time;safety evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood, urine, fecal routine, liver, renal function, coagulation function; | — |
Countries
China
Contacts
Public ContactYu-min Li
Lanzhou University
Outcome results
None listed